A failed trial for a heart drug casts shadow over rivals developing similar therapies

A clinical trial of a heart drug failed to demonstrate cardiovascular benefit despite reducing Lp(a) levels, according to full trial data released. The result affects the development pathway for other drugs in the same class that also target Lp(a) reduction. Competing pharmaceutical companies are developing similar therapies based on the same mechanism.

• MarketWatch — A failed trial for a heart drug casts shadow over rivals developing similar therapies

Next story